Streetbeat News

Products Services

SPEC

Spectaire Holdings Inc. (NASDAQ:SPEC) has announced a manufacturing financing agreement with Viva Capital Funding, LLC to support the mass production of its AireCore units. This agreement, along with the outsourcing of manufacturing to Columbia Tech, a subsidiary of Coghlin Companies, is expected to enable Spectaire to achieve positive free cash flow more quickly by reducing working capital needs and creating an asset-light production model. The AireCore units, which have begun shipping to customers, are priced at $2000 with an additional $1000 annual recurring revenue. The company's CFO and CEO believe this will help scale operations and address the growing market for emissions reduction technology.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 1:20 pm

GRFS

GigaGen, a subsidiary of Grifols, has received FDA clearance to begin a Phase 1 trial of its oncology drug candidate, GIGA-564, for the treatment of solid tumors.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 1:15 pm

LCFY

Locafy Limited (NASDAQ: LCFY), a SaaS company specializing in search engine marketing, announced its first subscription contract from a U.S.-based media publisher to improve online rankings for advertorials using Locafy's Keystone technology. This follows successful trials showing the technology's ability to rank advertorials on Page 1 of Google search results. The contract could lead to recurring revenue as Locafy works to expand its technology's use across the publisher's advertising agency clients. The market for Locafy's Article Accelerator is substantial and largely untapped, with potential growth as AI-generated content increases.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 1:13 pm

BKR

CVX

Baker Hughes (NASDAQ:BKR) has entered into a 20-year agreement with Chevron Australia to provide its Aptara Subsea production systems for future offshore developments. The agreement emphasizes Australian Industry Participation and aims to drive down costs and boost efficiency in energy projects. Baker Hughes will consolidate regional deliveries of its 7" Aptara Subsea Production systems, which are designed to minimize complexities and enhance project returns.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 1:12 pm

CRL

Charles River Laboratories International, Inc. (NYSE:CRL) has finalized an agreement with CELLphenomics to expand its 3D in vitro testing services for cancer therapy drug screening. CELLphenomics' PD3D® tumor model platform will enhance Charles River's offerings, providing clients access to over 500 complex in vitro models from more than 20 tumor entities. The partnership will also allow CELLphenomics to utilize Charles River's database of over 700 tumor models for developing PD3D models, increasing the translational relevance of both companies' platforms.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 1:12 pm

ACLS

Axcelis Technologies, Inc. (NASDAQ:ACLS) has announced the shipment of multiple Purion H SiC Power Series and Purion M SiC Power Series ion implanters to power device chipmakers in Europe and Asia. These systems will be used in high volume production of power devices for EV applications. Axcelis has also closed a deal for a Purion H200 SiC Power Series evaluation tool in Europe. The Purion Power Series is designed to handle various wafer sizes and types, offering high throughput and capital efficiency for power device manufacturing.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 1:11 pm

BPMC

Blueprint Medicines Corporation's AYVAKYT (avapritinib) has received approval from the European Commission to treat adult patients with indolent systemic mastocytosis (ISM) who have moderate to severe symptoms not adequately controlled by symptomatic treatment. This marks AYVAKYT as the first and only approved therapy for ISM in Europe.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 1:07 pm

EDAP

EDAP TMS SA announced that the French National Authority for Health (HAS) has issued a favorable recommendation for the reimbursement of its high-intensity focused ultrasound (HIFU) therapy for prostate cancer treatment. This is a significant step towards securing final reimbursement in France.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 1:06 pm

EKSO

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) announced CMS approval for HCPCS Code K1007 to bill Medicare for Ekso Indego Personal, an exoskeleton for individuals with spinal cord injuries. CMS proposed a payment of $94,617 for devices under this code, with a final decision expected in February 2024. The code will take effect on April 1, 2024. The approval is seen as an inflection point for the device, expected to improve health outcomes and quality of life for SCI patients. Ekso presented at the HCPCS public meeting, emphasizing the device's benefits, and received support from Dr. Alberto Esquenazi, who noted the clinical benefits of Ekso devices in rehabilitation.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 1:06 pm

ECOR

electroCore has been granted U.S. Patent No. 11,839,764 for a system that uses electrical stimulation to treat medical conditions such as primary headaches. The system includes software on a mobile device to control the electrical impulses delivered by a stimulator targeting nerves in the head or neck.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 1:06 pm